Search

Displaying results 5141 - 5150 of 10000 in total
  1. Drug

    Cefapirin

    go.drugbank.com/drugs/DB01139
    ApprovedVet approved

    Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms. … Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations.

  2. Drug

    Aprindine

    go.drugbank.com/drugs/DB01429
    Experimental

    Aprindine is a cardiac depressant used in arrhythmias.

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ib
  3. Drug

    XP12B

    go.drugbank.com/drugs/DB04928
    Investigational

    XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.

  4. Drug

    OPC-28326

    go.drugbank.com/drugs/DB05461
    Experimental

    It is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome. … At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary

  5. Drug

    XTL-6865

    go.drugbank.com/drugs/DB06058
    Investigational

    It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.

  6. Drug

    Oxolamine

    go.drugbank.com/drugs/DB13216
    Approved

    Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant [L5416]. It is listed as a prescription drug in New Zealand legislation [L5419]. … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422].

  7. Drug

    Binodenoson

    go.drugbank.com/drugs/DB04853
    Investigational

    This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion … Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor.

  8. Drug

    Prolectin-M

    go.drugbank.com/drugs/DB16521
    Investigational

    [L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)). … Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin.

  9. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    It was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease). … VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).

  10. Drug

    Anagliptin

    go.drugbank.com/drugs/DB12417
    Investigational

    Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.

    Categories: DPP-IV Inhibitors